Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The European Union Allocates Six Million Euros to Study Prevention Strategies Tumors Caused by HPV

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
The human papillomavirus (HPV) is responsible for cervical cancer and is behind a significant percentage of other tumors such as vulva , vagina, penis, anus, and oropharynx.

It is estimated that, in Europe , every year 30,000 women die as a result of cervical cancer, especially in the Eastern countries , where screening programs are not consolidated.

The consortium CoheaHr wants to provide scientific evidence for the clinical effectiveness and cost - effectiveness of different strategies to prevent cervical cancer throughout the European Union. To assess strategies focus on screening for HPV detection and vaccination. Specifically, the consortium conducted four clinical trials:

•    Compare the results of sampling for HPV testing when performed by the patient herself and when you get a health care professional, and their possible implementation as a method to increase screening coverage.
•    To determine the subsequent most appropriate time intervals and the use of HPV screening test for subsequent monitoring of :
      o    Women in age to start screening, vaccinated  during adolescence
      o    Young women vaccinated two years before the start of screening.
•    To assess the feasibility and acceptance of the HPV vaccine by the women entering the routine screening between 25-45 years.

The results of the different components will be incorporated into transmission models, economic and impact made by the consortium to make projections of different preventive interventions.

The consortium is committed to producing systematic reviews that allow summarizing the evidence generated in the medical literature and contribute to the dissemination of research results.

CoheaHr consortium with the participation of twelve partners from eleven countries: Amsterdam, Barcelona, Tampere, London, Turin, Stockholm, Brussels, Ljubljana, Lyon, Copenhagen, Reims and Wolfsburg. The Research Program in Cancer Epidemiology ICO lead two areas of work, the study of acceptance of the vaccine in women aged 25-45 years and scientific dissemination activities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!